Hot Topics: Covalent Drug Discovery 2024

BMCS Hot Topics: Covalent Drug Discovery

Thursday 16th May, 2024 (afternoon)

Online event

Important links and downloads
X Hashtag – #HotTopicsCDD24
To download the first announcement poster, click here
To download the second announcement poster, click here

Covalent binding has emerged as a key strategy in contemporary drug discovery. This online, half-day meeting will bring together experts from both academia and industry to discuss recent advances in using covalent small molecules to target challenging protein targets.

The BMCS Hot Topics online meetings are intended to highlight breaking areas of research in fields of science relevant to drug discovery. They will run as stand-alone half-day virtual events, 2-3 times per year. The programme will be targeted towards researchers working who would like to enhance their understanding of these nascent or developing fields.

Registration is now closed.
RSC Member* £35
Non-Member £65
RSC Student** Member* £25
Student** Non-Member £40

* Member is a paid-up member of the RSC
** Student rates apply to undergraduate and post-graduate students only, but not post-doctoral students.

Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.

The organising committee are seeking sponsorship from organisations supporting the low registration fees offered to students. 


Chair: Harriet Riley, RSC
13:00 Opening Remarks



Targeted Covalent Ligands to address Drug Discovery Challenges
Elena De Vita,
Queen Mary University of London



Development of AZ’s Covalent Hit-Identification Platform
Simon Lucas, AstraZeneca
14:15 Break



Mechanism of action and therapeutic potential of covalent LSD1 inhibitors
Tamara Maes, Oryzon Genomics, Spain



Reimagining Druggability using Chemoproteomic Platforms
Dan Nomura, University of California, USA
15:45 Break



Covalent Drug Discovery – Beyond Cysteine Targeting
Lyn Jones, Dana-Farber Cancer Institute, USA



Inhibiting KRAS:  Strategies, Structures, and Lessons Learned in the Invention of Sotorasib
Brian Lanman, Amgen
17:30 Close


With thanks to our sponsors for the meeting

Organising Committee
Adrian Hall, UCB
Daniel O Donovan, AstraZeneca
Harriet Riley, RSC
Chris Swain, Cambridge MedChem Consulting

Secretariat Contact
Hg3 Conferences Ltd
+44 (0)1423 529333